WTG
JANX icon

West Tower Group’s Janux Therapeutics JANX Stock Holding History

West Tower Group’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$397K Buy
+23,000
New +$386K 1.47% 21

Other funds holding JANX

Congress Asset Management
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
FFO
Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
Mather Group
Mather Group Chicago, Illinois $11.8B AUM 12.84% 1-Year Est. Return
EP
Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return
MAM
Marquette Asset Management Minneapolis, Minnesota $766M AUM 16.04% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return

West Tower Group's JANX Position: Q3 2026 in Review

West Tower Group opened a new position in Janux Therapeutics (JANX) in Q3 2026: 23,000 shares worth $397K. The stake represents 1.47% of the portfolio and ranks #21 among its holdings.

10 funds tracked by Wall St. Rank hold JANX as of Q3 2026.

  • West Tower Group held 23,000 shares of Janux Therapeutics worth $397K as of Q3 2026.
  • Janux Therapeutics was a new West Tower Group position in Q3 2026.
  • Janux Therapeutics made up 1.47% of West Tower Group's portfolio in Q3 2026, its #21 holding.
  • 10 funds tracked by Wall St. Rank held Janux Therapeutics as of Q3 2026.

Based on West Tower Group's 13F filing for Q3 2026, filed 14 Oct 2026.